Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Hegde, Pushpa ^a,b   Maddur, Mohan S ^a,c,d   Friboulet, Alain ^b   Bayry, Jagadeesh ^a,c,d   Kaveri, Srini V ^a,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; VISCUM ALBUM EXTRACT; PLANT EXTRACT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME IMMUNOASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHYTOCHEMISTRY; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VISCUM ALBUM; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; SECRETION; TUMOR CELL LINE;

VISCUM ALBUM;

ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; PLANT EXTRACTS; VISCUM ALBUM;

EID: 80054718264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026312     Document Type: Article

References (75)

1. Olsnes S, Stirpe F, Sandvig K, Pihl A, (1982) Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 257: 13263-13270.
2. Khwaja TA, Dias CB, Pentecost S, (1986) Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology 43 (Suppl 1): 42-50.
3. Franz H, Ziska P, Kindt A, (1981) Isolation and properties of three lectins from mistletoe (Viscum album L.). Biochem J 195: 481-484.
4. Urech K, Schaller G, Jaggy C, (2006) Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 56: 428-434.
5. Kaegi E, (1998) Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158: 1157-1159.
6. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B, (2004) [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung 54: 456-466.
7. Klopp R, Schmidt W, Werner E, Werner M, Niemer W, et al. (2005) Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res 25: 601-610.
8. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B, (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 55: 38-49.
9. Bussing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, et al. (2005) Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res 25: 4753-4757.
10. Kienle GS, Kiene H, (2010) Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9: 142-157.
11. Radenkovic M, Ivetic V, Popovic M, Mimica-Dukic N, Veljkovic S, (2006) Neurophysiological effects of mistletoe (Viscum album L.) on isolated rat intestines. Phytother Res 20: 374-377.
12. Tusenius KJ, Spoek AM, van Hattum J, (2005) Exploratory study on the effects of treatment with two mistletoe preparations on chronic hepatitis C. Arzneimittelforschung 55: 749-753.
13. Tenorio FA, del Valle L, Gonzalez A, Pastelin G, (2005) Vasodilator activity of the aqueous extract of Viscum album. Fitoterapia 76: 204-209.
14. Karagoz A, Onay E, Arda N, Kuru A, (2003) Antiviral potency of mistletoe (Viscum album ssp. album) extracts against human parainfluenza virus type 2 in Vero cells. Phytother Res 17: 560-562.
15. Tusenius KJ, Spoek JM, Kramers CW, (2001) Iscador Qu for chronic hepatitis C: an exploratory study. Complement Ther Med 9: 12-16.
16. Christen-Clottu O, Klocke P, Burger D, Straub R, Gerber V, (2010) Treatment of clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album austriacus). J Vet Intern Med 24: 1483-1489.
17. Bussing A, Schietzel M, (1999) Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res 19: 23-28.
18. Stein GM, Pfuller U, Schietzel M, Bussing A, (2000) Toxic proteins from European mistletoe (Viscum album L.): increase of intracellular IL-4 but decrease of IFN-gamma in apoptotic cells. Anticancer Res 20: 1673-1678.
19. Stein GM, Pfuller U, Schietzel M, Bussing A, (2000) Intracellular expression of IL-4 and inhibition of IFN-gamma by extracts from European mistletoe is related to induction of apoptosis. Anticancer Res 20: 2987-2994.
20. Duong Van Huyen JP, Bayry J, Delignat S, Gaston AT, Michel O, et al. (2002) Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol Med 8: 600-606.
21. Duong Van Huyen JP, Delignat S, Kazatchkine MD, Kaveri SV, (2003) Comparative study of the sensitivity of lymphoblastoid and transformed monocytic cell lines to the cytotoxic effects of Viscum album extracts of different origin. Chemotherapy 49: 298-302.
22. Duong Van Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, et al. (2006) Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 243: 32-37.
23. Heinzerling L, von Baehr V, Liebenthal C, von Baehr R, Volk HD, (2006) Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol 26: 347-359.
24. Stein GM, Bussing A, Schietzel M, (2002) Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 22: 4215-4219.
25. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, et al. (1995) A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14: 295-304.
26. Elluru SR, Duong van Huyen JP, Delignat S, Kazatchkine MD, Friboulet A, et al. (2008) Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 8: 161.
27. Duong Van Huyen JP, Sooryanarayana, Delignat S, Bloch MF, Kazatchkine MD, et al. (2001) Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectin. Chemotherapy 47: 366-376.
28. Yoon TJ, Yoo YC, Kang TB, Her E, Kim SH, et al. (2001) Cellular and humoral adjuvant activity of lectins isolated from Korean mistletoe (Viscum album colaratum). Int Immunopharmacol 1: 881-889.
29. Gardin NE, (2009) Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series. Phytother Res 23: 407-411.
30. Frank U, Engels I, Wagner A, Lacour M, Daschner FD, (2003) Influence of mistletoe (Viscum album) extracts on phagocytosis/burst activity of human phagocytes. Eur J Clin Microbiol Infect Dis 22: 501-503.
31. Medzhitov R, (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
32. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J, (2009) Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30: 287-295.
33. Medzhitov R, (2010) Inflammation 2010: new adventures of an old flame. Cell 140: 771-776.
34. Bayry J, (2010) Immunology: TL1A in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 6: 67-68.
35. Libby P, (2007) Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 65: S140-146.
36. Maddur MS, Kaveri SV, Bayry J, (2010) Basophils as antigen presenting cells. Trends Immunol 31: 45-48.
37. Kaveri SV, Mouthon L, Bayry J, (2010) Basophils and nephritis in lupus. N Engl J Med 363: 1080-1082.
38. Tomlinson KL, Davies GC, Sutton DJ, Palframan RT, (2010) Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite. PLoS One 5: e13136.
39. Bayry J, Siberil S, Triebel F, Tough DF, Kaveri SV, (2007) Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 12: 548-552.
40. Achoui M, Appleton D, Abdulla MA, Awang K, Mohd MA, et al. (2010) In vitro and in vivo anti-inflammatory activity of 17-O-acetylacuminolide through the inhibition of cytokines, NF-kappaB translocation and IKKbeta activity. PLoS One 5: e15105.
41. Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J, (2009) Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 174: 1575-1587.
42. Correa-Costa M, Semedo P, Monteiro AP, Silva RC, Pereira RL, et al. (2010) Induction of heme oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis. PLoS One 5: e14298.
43. Bayry J, (2009) Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat Rev Rheumatol 5: 244-245.
44. Hegeman MA, Hennus MP, van Meurs M, Cobelens PM, Kavelaars A, et al. (2010) Angiopoietin-1 treatment reduces inflammation but does not prevent ventilator-induced lung injury. PLoS One 5: e15653.
45. Bayry J, Negi VS, Kaveri SV, (2011) Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 7: 349-359.
46. Goldyne ME, Winkelmann RK, Ryan RJ, (1973) Prostaglandin activity in human cutaneous inflammation: detection by radioimmunoassay. Prostaglandins 4: 737-749.
47. Passwell J, Levanon M, Davidsohn J, Ramot B, (1983) Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity. Clin Exp Immunol 51: 61-68.
48. Karmali RA, Welt S, Thaler HT, Lefevre F, (1983) Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer 48: 689-696.
49. Redondo S, Ruiz E, Gordillo-Moscoso A, Navarro-Dorado J, Ramajo M, et al. (2011) Overproduction of cyclo-oxygenase-2 (COX-2) is involved in the resistance to apoptosis in vascular smooth muscle cells from diabetic patients: a link between inflammation and apoptosis. Diabetologia 54: 190-199.
50. Chun KS, Surh YJ, (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68: 1089-1100.
51. Chell S, Kaidi A, Williams AC, Paraskeva C, (2006) Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766: 104-119.
52. Cerella C, Sobolewski C, Dicato M, Diederich M, (2010) Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol 80: 1801-1815.
53. Vane JR, Botting RM, (1996) Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 102 pp. 9-21.
54. Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, et al. (2008) Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol 586: 340-349.
55. Hamsa TP, Kuttan G, (2011) Evaluation of the anti-inflammatory and anti-tumor effect of ipomoea obscura (L) and its mode of action through the inhibition of pro inflammatory cytokines, nitric oxide and COX-2. Inflammation 34: 171-183.
56. Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, et al. (2010) Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 5: e11610.
57. Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R, (2006) Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 228: 1-15.
58. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, et al. (2009) Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125: 2187-2197.
59. Kale A, Gawande S, Kotwal S, (2008) Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22: 567-577.
60. Habib SH, Makpol S, Abdul Hamid NA, Das S, Ngah WZ, et al. (2008) Ginger extract (Zingiber officinale) has anti-cancer and anti-inflammatory effects on ethionine-induced hepatoma rats. Clinics (Sao Paulo) 63: 807-813.
61. Rosenkranz HS, Thampatty BP, (2003) SAR: flavonoids and COX-2 inhibition. Oncol Res 13: 529-535.
62. Torres Salazar A, Hoheisel J, Youns M, Wink M, (2011) Anti-inflammatory and anti-cancer activities of essential oils and their biological constituents. Int J Clin Pharmacol Ther 49: 93-95.
63. Jin M, Suh SJ, Yang JH, Lu Y, Kim SJ, et al. (2010) Anti-inflammatory activity of bark of Dioscorea batatas DECNE through the inhibition of iNOS and COX-2 expressions in RAW264.7 cells via NF-kappaB and ERK1/2 inactivation. Food Chem Toxicol 48: 3073-3079.
64. Hwang YP, Choi JH, Yun HJ, Han EH, Kim HG, et al. (2011) Anthocyanins from purple sweet potato attenuate dimethylnitrosamine-induced liver injury in rats by inducing Nrf2-mediated antioxidant enzymes and reducing COX-2 and iNOS expression. Food Chem Toxicol 49: 93-99.
65. Hong J, Sang S, Park HJ, Kwon SJ, Suh N, et al. (2006) Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives. Carcinogenesis 27: 278-286.
66. Min KJ, Choi K, Kwon TK, (2011) Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. Int Immunopharmacol 11: 1137-1142.
67. Bereswill S, Munoz M, Fischer A, Plickert R, Haag LM, et al. (2010) Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 5: e15099.
68. Orhan DD, Kupeli E, Yesilada E, Ergun F, (2006) Anti-inflammatory and antinociceptive activity of flavonoids isolated from Viscum album ssp. album. Z Naturforsch C 61: 26-30.
69. Lavastre V, Cavalli H, Ratthe C, Girard D, (2004) Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo. Clin Exp Immunol 137: 272-278.
70. Pairet M, Engelhardt G, (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 10: 1-17.
71. Pozzi A, Zent R, (2009) Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. Wiley Interdiscip Rev Syst Biol Med 1: 254-272.
72. Tetsuka T, Baier LD, Morrison AR, (1996) Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation. J Biol Chem 271: 11689-11693.
73. Meyer-Kirchrath J, Schror K, (2000) Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Curr Med Chem 7: 1121-1129.
74. Chrubasik S, Kunzel O, Model A, Conradt C, Black A, (2001) Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. Rheumatology (Oxford) 40: 1388-1393.
75. Cravotto G, Boffa L, Genzini L, Garella D, (2010) Phytotherapeutics: an evaluation of the potential of 1000 plants. J Clin Pharm Ther 35: 11-48.